BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer

NCT06123884 | Recruiting Phase 2

• 1 other identifier: BAT-1308-002-CR
• Study Type: interventional
• Target: 526
• Locations: 1 country
• Sites: 1

Brief Summary

Phase II study: a study to explore the safety and preliminary efficacy of BAT1308 combined with platinum-based chemotherapy ± Bevacizumab Phase III study: a confirmatory study to evaluate the safety and efficacy of BAT1308 combined with platinum-based chemotherapy ± Bevacizumab as first-line therapy for PD-L1-positive (CPS ≥ 1) persistent, recurrent or metastatic cervical cancer

Conditions

Cervical Cancer

Outcome Measures

Primary Outcomes (2)

• Progression-Free Survival (PFS)

  Tumor assessment is performed according to RECIST 1.1. Tumor imaging assessment is performed every 9 weeks (±7 days) after the first administration until week 54. After that, it is performed once every 12 weeks (±7 days) until disease progression, withdrawal from the group, loss to follow-up, death, or 24 months after the first study drug administration at the longest distance, whichever occurs first.

  From first administration to the occurrence of objective tumor progression or all-cause death (whichever occurs first), the assessment period lasts up to two years.

• Overall Survival

  Tumor assessment is performed according to RECIST 1.1. Tumor imaging assessment is performed every 9 weeks (±7 days) after the first administration until week 54. After that, it is performed once every 12 weeks (±7 days) until disease progression, withdrawal from the group, loss to follow-up, death, or 24 months after the first study drug administration at the longest distance, whichever occurs first.

  From the date of first administration to the time of death due to any cause, the assessment period will last up to two years.

Secondary Outcomes (7)

• Vital signs

  Through study completion, an average of 2 years

• Physical examination

  Through study completion, an average of 2 years

• Laboratory Examination

  Through study completion, an average of 2 years

• Adverse event

  Through study completion, an average of 2 years

• Objective response rate (ORR)

  Through study completion, an average of 2 years

Study Arms (2)

BAT1308

EXPERIMENTAL

Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W)

Drug: Recombinant humanized anti-PD-1 monoclonal antibody injection; Drug: Cisplatin; Drug: Bevacizumab Injection; Drug: carboplatin; Drug: Paclitaxel for Injection

BAT1308 monoclonal antibody

PLACEBO COMPARATOR

Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W)

Drug: Recombinant humanized anti-PD-1 monoclonal antibody injection; Drug: Cisplatin; Drug: Bevacizumab Injection; Drug: carboplatin; Drug: Paclitaxel for Injection

Interventions

Recombinant humanized anti-PD-1 monoclonal antibody injection DRUG

Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W).

Also known as: BAT1308 injection

BAT1308; BAT1308 monoclonal antibody

Cisplatin DRUG

the usage and dosage should be determined by the investigator

Also known as: Shunbo

BAT1308; BAT1308 monoclonal antibody

Bevacizumab Injection DRUG

Strength 100 mg/4 mL, recommended dose 15 mg/kg body weight, administered every 3 weeks (15 mg/kg, Q3W)

Also known as: Pobevcy

BAT1308; BAT1308 monoclonal antibody

carboplatin DRUG

the usage and dosage should be determined by the investigator

Also known as: Bobei

BAT1308; BAT1308 monoclonal antibody

Paclitaxel for Injection DRUG

the usage and dosage should be determined by the investigator

Also known as: Tesu

BAT1308; BAT1308 monoclonal antibody

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Female patients, aged ≥18 years to ≤70 years, who voluntarily sign the informed consent form;
• With persistent, recurrent or metastatic (the Federation International of Gynecology and Obstetrics \[FIGO\] Stage IVB) cervical cancer confirmed histologically (pathological reports required), including pathological types of squamous cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma and clear-cell renal-cell carcinoma, not amenable to radical surgery and/or radical radiotherapy or radiochemotherapy, with no prior systemic anti-tumor therapy for persistent, recurrent or metastatic cervical cancer;
• Subjects should be positive for PD-L1 expression (CPS ≥ 1) in tumor specimens by the central laboratory. Subjects should provide sufficient formalin-fixed paraffin-embedded (FFPE) specimens or sections (6 sections recommended, not less than 3 sections), and be willing to undergo a tumor tissue biopsy for PD-L1 testing when necessary. The archival tissues must be representative tumor specimens collected within three years or unstained continuous sections of FFPE tumor tissues freshly resected within six months, and relevant pathological reports of the aforementioned specimens must also be provided. Both surgical resection and biopsy are acceptable methods for acquiring fresh tissue specimens; fine-needle aspiration and liquid-based cytology (TCT) samples (i.e., samples lacking complete tissue structures and providing only cell suspension and/or cell smears) are not acceptable; decalcified bone metastasis tumor tissue specimens are not acceptable;
• At least one measurable tumor lesion per RECIST v1.1; lesions at sites previously treated with radiotherapy or other loco-regional therapies can only be considered as non-target lesions, unless unequivocal progression of the lesion occurs or the tumor activity of the lesion is confirmed by biopsy and the lesion is measurable
• Life expectancy ≥12 weeks as evaluated by the investigator;
• Eastern Cooperative Oncology Group (ECOG) Performance Status score 0 or 1;
• Female patients of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose and are willing to take effective birth control/contraceptive methods to prevent pregnancy during the study until 6 months after the last dose of the study drug. Postmenopausal women must have amenorrhea for at least 12 months before they are considered as women of non-childbearing potential.
• \. Able to understand trial requirements, willing and able to comply with the trial and follow-up procedures.

You may not qualify if:

• Subjects with other pathological types of cervical cancer, such as small cell carcinoma, sarcoma, etc.;
• Pregnant or lactating women;
• Prior radiotherapy within 14 days before the first dose. Except for palliative area radiotherapy for bone metastases for which pain cannot be effectively controlled by systemic therapy or local pain relief (radiotherapy area \< 5% of bone marrow area); prior chemotherapeutic agents for increasing the sensitization to radiotherapy within 14 days before the first dose; prior use of traditional Chinese patent medicines or treatment with anti-tumor related functions as specified in the NMPA-approved package inserts within 14 days before the first dose, or Chinese herbal medicines for anti-tumor purposes clearly documented in the medical record ;
• Patients who received live/attenuated vaccines and mRNA vaccines within 4 weeks prior to screening or scheduled to receive those vaccines during the study period;
• Any prior treatments targeting the mechanism of tumor immunity, such as immune checkpoint inhibitors (e.g., anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies, etc.) or therapies that target immune co-stimulatory molecules (e.g., antibodies targeting ICOS, CD40, CD137, GITR, OX40, etc.);
• AEs caused by prior anti-tumor therapy that are still \> Grade 1 (as per CTCAE v5.0) before the first dose of the study drug (except for AEs, such as alopecia, fatigue, etc., that cannot be recovered to ≤ Grade 1 and will remain stable for a long time as judged by the investigator based on actual clinical situations, except for Grade 2 peripheral neurotoxicity, and hypothyroidism stabilized by hormone replacement therapy); patients who previously experienced ≥ Grade 3 irAEs or discontinued immunotherapy due to irAEs of any grade;
• Active leptomeningeal disease or poorly controlled brain metastases. Patients with suspected or confirmed brain metastases are allowed to be enrolled if they have no obvious symptoms and the results of imaging examinations performed at least 28 days before the first dose of the study drug showed stable disease and no treatment (e.g., radiotherapy, surgery, or corticosteroid treatment) is required to control the symptoms of brain metastases within 28 days before the first dose of the study drug;
• Patients who underwent major organ surgery (excluding aspiration biopsy) or experienced significant trauma within 4 weeks before the first dose of the study drug, or those who require elective surgery during the trial period;
• Subjects with serious infections within 4 weeks before the first dose, including but not limited to the infection-related complications, bacteremia and severe pneumonia requiring hospitalization; subjects with active infection before the first dose are excluded;
• Patients with the following infectious diseases: human immunodeficiency virus (HIV) infection; active hepatitis B virus infection \[hepatitis B surface antigen (HBsAg) positive, and the result for hepatitis B virus deoxyribonucleic acid (HBV-DNA) test \> 500 IU/ml or 103 copies/ml or above the upper limit of normal at the testing institution\]; hepatitis C virus infection \[anti-HCV antibodies and hepatitis C virus ribonucleic acid (HCV-RNA) test positive\]; Treponema pallidum antibody positive and rapid plasma reagin (RPR) positive;
• Subjects with tuberculosis untreated or under treatment, including but not limited to pulmonary tuberculosis; patients whose tuberculosis was cured after standardized anti-tuberculosis treatment as confirmed by the investigator may be included;
• Subjects with known history of severe allergy or prior ≥ Grade 3 allergic reactions to macromolecular protein preparations/monoclonal antibodies, and any component of the investigational drug;
• Known to have any contraindication to cisplatin/carboplatin or paclitaxel, or allergy to any of their components;
• Clinically significant hydronephrosis that cannot be relieved by nephrostomy or ureteral stent insertion as judged by the investigator;
• Subjects with uncontrollable pleural effusion, pericardial effusion, or ascites requiring repeated drainage;

Sponsors & Collaborators

• Bio-Thera Solutions: lead

Study Sites (1)

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology

Wuhan, Hubei, China

RECRUITING

MeSH Terms

Conditions

Uterine Cervical Neoplasms

Interventions

Cisplatin; Bevacizumab; Carboplatin; Paclitaxel; Injections

Condition Hierarchy (Ancestors)

Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Uterine Cervical Diseases; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Intervention Hierarchy (Ancestors)

Chlorine Compounds; Inorganic Chemicals; Nitrogen Compounds; Platinum Compounds; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins; Coordination Complexes; Organic Chemicals; Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Diterpenes; Terpenes; Drug Administration Routes; Drug Therapy; Therapeutics

Study Officials

• Qinglei Gao, Ph.D

  Tongji Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Juan Chen

CONTACT

18971436492; jchen@bio-thera.com

Zhaohe Wang, Ph.D

CONTACT

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 21, 2023
• First Posted: November 9, 2023
• Study Start: December 13, 2023
• Primary Completion (Estimated): September 1, 2026
• Study Completion (Estimated): January 1, 2027
• Last Updated: February 10, 2025

Record last verified: 2025-02

Locations

CN (1)